Kim HD - Search Results

1

Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study.

Kim HD, Lee JS, Yook JH, Ryu MH, Park YK, Kim JY, Kim YW, Oh SC, Kim JG, Cheong JH, Jeong O, Noh SH, Kang YK. Kim HD, et al. Among authors: kim jy, kim jg, kim yw. Gastric Cancer. 2022 Jan;25(1):170-179. doi: 10.1007/s10120-021-01243-z. Epub 2021 Sep 2. Gastric Cancer. 2022. PMID: 34476643

2

Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel.

Kim HD, Ryu MH, Yoon S, Na YS, Moon M, Lee H, Song HG, Kang YK. Kim HD, et al. Chin J Cancer Res. 2020 Oct 31;32(5):621-630. doi: 10.21147/j.issn.1000-9604.2020.05.07. Chin J Cancer Res. 2020. PMID: 33223757 Free PMC article.

3

Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.

Bang Y, Yoo C, Lonardi S, Kim HD, Vivaldi C, Rimini M, Frassineti GL, Park SR, Rizzato MD, Ryu MH, Salani F, Rapposelli IG, Ryoo BY, Zagonel V, Massa V, Valgiusti M, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A. Bang Y, et al. Among authors: kim hd. Target Oncol. 2021 May;16(3):401-410. doi: 10.1007/s11523-021-00797-3. Epub 2021 Mar 1. Target Oncol. 2021. PMID: 33646487

4

Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5.

Kim HD, Im HS, Kim JH, Jeong H, Yoon SK, Park I, Lee JL. Kim HD, et al. Among authors: kim jh. Cancer Res Treat. 2021 Oct;53(4):1166-1173. doi: 10.4143/crt.2021.091. Epub 2021 Mar 4. Cancer Res Treat. 2021. PMID: 33677847 Free PMC article.

5

Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.

Bang Y, Yoo C, Lonardi S, Kim HD, Vivaldi C, Rimini M, Frassineti GL, Park SR, Rizzato MD, Ryu MH, Salani F, Rapposelli IG, Ryoo BY, Zagonel V, Massa V, Valgiusti M, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A. Bang Y, et al. Among authors: kim hd. Target Oncol. 2021 May;16(3):411-412. doi: 10.1007/s11523-021-00808-3. Target Oncol. 2021. PMID: 33738697 No abstract available.

6

Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.

Casadei-Gardini A, Rimassa L, Rimini M, Yoo C, Ryoo BY, Lonardi S, Masi G, Kim HD, Vivaldi C, Ryu MH, Rizzato MD, Salani F, Bang Y, Pellino A, Catanese S, Burgio V, Cascinu S, Cucchetti A. Casadei-Gardini A, et al. Among authors: kim hd. J Cancer Res Clin Oncol. 2021 Dec;147(12):3665-3671. doi: 10.1007/s00432-021-03602-w. Epub 2021 Mar 20. J Cancer Res Clin Oncol. 2021. PMID: 33745079

7

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery.

Jeong H, Park KJ, Lee Y, Kim HD, Kim JH, Yoon S, Hong B, Lee JL. Jeong H, et al. Among authors: kim hd, kim jh. Cancer Res Treat. 2022 Jan;54(1):226-233. doi: 10.4143/crt.2021.365. Epub 2021 May 6. Cancer Res Treat. 2022. PMID: 33957019 Free PMC article.

8

Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib.

Rimini M, Yoo C, Lonardi S, Masi G, Piscaglia F, Kim HD, Rizzato MD, Salani F, Ielasi L, Forgione A, Bang Y, Soldà C, Catanese S, Sansone V, Ryu MH, Ryoo BY, Burgio V, Cucchetti A, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: kim hd. Hepatol Res. 2021 Jul;51(7):796-802. doi: 10.1111/hepr.13669. Epub 2021 May 26. Hepatol Res. 2021. PMID: 34005839

9

Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab.

Cho H, Ryu MH, Lee HE, Kim HD, Kang YK. Cho H, et al. Among authors: kim hd. Cancer Immunol Immunother. 2022 Apr;71(4):829-838. doi: 10.1007/s00262-021-03035-x. Epub 2021 Aug 22. Cancer Immunol Immunother. 2022. PMID: 34420059 Free PMC article.

10

Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab.

Kim HD, Ryu MH, Park YS, Lee SY, Moon M, Kang YK. Kim HD, et al. Gastric Cancer. 2022 Jan;25(1):226-234. doi: 10.1007/s10120-021-01233-1. Epub 2021 Sep 1. Gastric Cancer. 2022. PMID: 34468871

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,244 results

Search Page

Filters